- Home
- LPTX vs OSRH Comparison
LPTX vs OSRH Comparison
Compare LPTX & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- OSRH
- Stock Information
- Founded
- LPTX 2011
- OSRH N/A
- Country
- LPTX United States
- OSRH United States
- Employees
- LPTX N/A
- OSRH N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- OSRH
- Sector
- LPTX Health Care
- OSRH
- Exchange
- LPTX Nasdaq
- OSRH Nasdaq
- Market Cap
- LPTX 11.1M
- OSRH 11.1M
- IPO Year
- LPTX N/A
- OSRH N/A
- Fundamental
- Price
- LPTX $0.29
- OSRH $0.60
- Analyst Decision
- LPTX Hold
- OSRH
- Analyst Count
- LPTX 1
- OSRH 0
- Target Price
- LPTX N/A
- OSRH N/A
- AVG Volume (30 Days)
- LPTX 2.0M
- OSRH 13.8M
- Earning Date
- LPTX 08-14-2025
- OSRH 08-14-2025
- Dividend Yield
- LPTX N/A
- OSRH N/A
- EPS Growth
- LPTX N/A
- OSRH N/A
- EPS
- LPTX N/A
- OSRH N/A
- Revenue
- LPTX N/A
- OSRH $104,735.00
- Revenue This Year
- LPTX N/A
- OSRH N/A
- Revenue Next Year
- LPTX N/A
- OSRH N/A
- P/E Ratio
- LPTX N/A
- OSRH N/A
- Revenue Growth
- LPTX N/A
- OSRH N/A
- 52 Week Low
- LPTX $0.22
- OSRH $0.45
- 52 Week High
- LPTX $4.79
- OSRH $13.40
- Technical
- Relative Strength Index (RSI)
- LPTX 46.11
- OSRH 42.25
- Support Level
- LPTX $0.28
- OSRH $0.74
- Resistance Level
- LPTX $0.31
- OSRH $1.24
- Average True Range (ATR)
- LPTX 0.04
- OSRH 0.10
- MACD
- LPTX 0.00
- OSRH 0.03
- Stochastic Oscillator
- LPTX 39.39
- OSRH 18.74
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.